Chalin Arnaud, Arvor Antoine, Hervault Anne-Sophie, Plaisance Marc, Niol Léa, Simon Stéphanie, Volland Hervé
NG Biotech - Research and Development Department, Guipry-Messac, France.
Université Paris-Saclay, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (INRAE), Médicaments et Technologies pour la Santé (MTS), Service de Pharmacologie et d'Immunoanalyse (SPI), Laboratoire d'Etudes et de Recherches en Immunoanalyse (LERI), Gif-sur-Yvette, France.
Front Microbiol. 2024 Jul 3;15:1439273. doi: 10.3389/fmicb.2024.1439273. eCollection 2024.
is a recently discovered yeast with a multi-drug resistant profile associated with high mortality rates. The rapid identification of in hospital settings is crucial to allow appropriate therapeutic and rapid implementation of infection management measures. The aim of this study was to develop a lateral flow immunoassay (LFIA) for the rapid identification of .
Highly specific monoclonal antibodies were obtained by immunizing mice with membrane proteins from which were then used to develop a LFIA whose performance was assessed by testing 12 strains of and 37 strains of other Candida species. Isolates were grown on either Sabouraud dextrose, CHROMagar Candida Plus or HardyCHROM + agar plates. The strains were also cultured on salt sabouraud-dextrose with chloramphenicol or a commercially available Salt-Sabouraud Dulcitol Broth with chloramphenicol and gentamicin, and processed using a simple centrifugation protocol to recover a pellet. Finally, the colonies or yeast extract were transferred to the LFIA to determine the specificity and sensitivity of the assay.
The LFIA reached 100% specificity and sensitivity from solid agar plates. For both enrichment broths, some Candida non-auris species were able to grow, but the LFIA remained 100% specific. The use of a dextrose-based sabouraud broth resulted in earlier identification with the LFIA, with most of the Candida auris strains detected at 24 h.
The developed LFIA prototype represents a powerful tool to fight the emerging threat of Candida auris. Clinical validation represents the next step.
是一种最近发现的酵母，具有与高死亡率相关的多重耐药性特征。在医院环境中快速鉴定对于采取适当的治疗措施和迅速实施感染管理措施至关重要。本研究的目的是开发一种用于快速鉴定的侧向流动免疫分析（LFIA）。
通过用的膜蛋白免疫小鼠获得高度特异性的单克隆抗体，然后将其用于开发LFIA，通过测试12株和37株其他念珠菌属物种来评估其性能。分离株在沙氏葡萄糖、CHROMagar念珠菌Plus或HardyCHROM +琼脂平板上生长。这些菌株还在含氯霉素的盐沙氏葡萄糖或市售的含氯霉素和庆大霉素的盐沙氏杜氏醇肉汤中培养，并使用简单的离心方案处理以回收沉淀。最后，将菌落或酵母提取物转移至LFIA以确定该分析的特异性和敏感性。
LFIA对固体琼脂平板的特异性和敏感性均达到100%。对于两种增菌肉汤，一些非耳念珠菌属物种能够生长，但LFIA的特异性仍为100%。使用基于葡萄糖的沙氏肉汤可通过LFIA更早地进行鉴定，大多数耳念珠菌菌株在24小时时被检测到。
所开发的LFIA原型是应对耳念珠菌新出现威胁的有力工具。临床验证是下一步。
